Table 1.
Subject Demographics
| Subject number | Age | Gender | Aura/no aura | Migraine-related dizziness? | Motion-sickness type | Prior triptans used |
|---|---|---|---|---|---|---|
| 1* | 26 | Female | Aura | Yes | Vestibular, visual | Rizatriptan, sumatriptan |
| 2 | 33 | Female | Aura | No | Visual | Eletriptan |
| 3* | 26 | Female | Aura | Yes | Vestibular | Eletriptan, rizatriptan, sumatriptan |
| 4 | 26 | Male | No aura | Yes | Vestibular, visual | Rizatriptan, sumatriptan |
| 5* | 45 | Female | No aura | No | Vestibular | Sumatriptan |
| 6* | 25 | Female | Aura | Yes | Vestibular, visual | Sumatriptan |
| 7* | 40 | Female | No aura | No | Vestibular | Eletriptan, rizatriptan, sumatriptan |
| 8* | 21 | Female | Aura | Yes | Visual | Sumatriptan |
| 9 | 25 | Female | No aura | No | Vestibular, visual | Sumatriptan |
| 10* | 22 | Female | No aura | Yes | Vestibular, visual | Sumatriptan |
| 11* | 24 | Female | No aura | Yes | Vestibular | Sumatriptan |
| 12* | 28 | Female | Aura | Yes | Vestibular | Sumatriptan |
| 13* | 31 | Female | Aura | No | Vestibular | Naratriptan |
| 14 | 30 | Female | Aura | Yes | Vestibular, visual | Sumatriptan |
| 15 | 27 | Female | Aura | No | Vestibular | Rizatriptan, sumatriptan |
| 16* | 41 | Female | Aura | Yes | Vestibular, visual | Sumatriptan |
| 17 | 24 | Female | Aura | No | Vestibular | Sumatriptan |
| 18 | 25 | Female | Aura | Yes | Vestibular | Frovatriptan |
| 19* | 41 | Male | No aura | Yes | Vestibular | Sumatriptan |
| 20 | 25 | Female | No aura | No | Vestibular, visual | Sumatriptan |
| 21* | 42 | Female | No aura | No | Vestibular, visual | Sumatriptan |
| 22 | 26 | Female | No aura | No | Vestibular, visual | Eletriptan, sumatriptan |
| 23* | 40 | Female | No aura | No | Vestibular, visual | Rizatriptan, sumatriptan |
| 24 | 41 | Female | Aura | No | Vestibular | Rizatriptan, sumatriptan |
| 25* | 42 | Female | Aura | No | Visual | Rizatriptan, sumatriptan |
* Included for statistical analysis